

**MERSEY PHARMACEUTICAL REGION ACCOUNT
PROFIT & LOSS ACCOUNT
FOR THE YEAR ENDED 31ST MARCH 2026**

	2026		2025	
	£	£	£	£
Income				
PharmOutcomes Stakeholder Sub-Licence	101,456.35		75,695.00	
Regional PCN Support Funds	49,920.00		48,463.00	
Bank interest received	1,280.36		-	
Total income		152,656.71		124,158.00
Expenses				
Pinnacle PharmOutcomes Licence	61,402.86		59,976.00	
GPCPCS LPC Allocation	46,600.00		17,085.00	
Meeting expenses	194.00		-	
Accountancy	520.00		452.00	
Vaccine Initiative Funding	15,000.00		-	
IT & sundry expenses	891.00		-	
HEE Project Work	2,381.19		-	
LPC PharmOutcomes Allocation	11,334.02		32,113.00	
Total expenses		138,323.07		109,626.00
Surplus/(loss) before tax		14,333.64		14,532.00
Corporation tax		243.39		-
Surplus/(loss) after tax		14,090.25		14,532.00

**MERSEY PHARMACEUTICAL REGION ACCOUNT
BALANCE SHEET
FOR THE YEAR ENDED 31ST MARCH 2026**

	2026		2025	
	£	£	£	£
Current Assets				
Lloyds regional community account	42,102.28		119,049.00	
Lloyds instant access account	10,109.65		-	
Lloyds deposit account	81,170.71		-	
Total current assets		133,382.64		119,049.00
Current Liabilities				
Corporation tax payable	243.39		-	
Total current liabilities		243.39		-
Net assets		133,139.25		119,049.00
Reserves		133,139.25		119,049.00

Dr Ian Cubbin
Treasurer

I. J. Cubbin

MERSEY PHARMACEUTICAL REGION ACCOUNT

ACCOUNT 'S REPORT

FOR THE YEAR ENDED 31ST MARCH 2026

accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us.

Haines Watts Wirral

Chartered Accountants

Chester Hou

Lloyd Drive

Cheshire Oaks Business Park

Ellesmere Port CH65 9HQ